The non-canonical ubiquitin activating enzyme UBA6 suppresses epithelial-mesenchymal transition of mammary epithelial cells

Xianpeng Liu*, Limin Sun, Demirkan B. Gursel, Chonghui Cheng, Sui Huang, Alfred W. Rademaker, Seema A. Khan, Jun Yin, Hiroaki Kiyokawa

*Corresponding author for this work

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Ubiquitination plays critical roles in the regulation of oncoproteins and tumor suppressors during carcinogenesis. The two ubiquitin activating enzymes (E1) in human genome, UBA1 and UBA6, initiate ubiquitination by ATP-dependent activation of ubiquitin. Recent evidence suggests that UBA1 and UBA6 play partially overlapped yet distinct roles in controlling the proteome. Here we demonstrate that ubiquitination pathways initiated specifically by UBA6 set a suppressive barrier against critical steps of mammary carcinogenesis such as loss of polarity, anoikis resistance and epithelialmesenchymal transition (EMT). Mammary epithelial MCF-10A cells expressing shRNA against UBA6 fail in establishing cell cycle arrest in response to detachment from extracellular matrix, confluency with fully engaged cell-cell contact or growth factor deprivation. Moreover, UBA6-deficient MCF-10A cells undergo spontaneous EMT under growth factor deprivation and exhibit accelerated kinetics of TGF-β-induced EMT. The Rho-GTPase CDC42 is one of the specific targets of UBA6-initiated ubiquitination and plays a key role in the function of UBA6 in controlling epithelial homeostasis, since a CDC42 inhibitor, ML141, rescues UBA6-deficient cells from the EMT phenotype. Immunohistochemical analysis of human breast cancer tissues demonstrates that 38% of invasive carcinomas express low or undetectable expression of UBA6, suggesting that downregulation of this non-canonical E1 plays a role in breast cancer development.

Original languageEnglish (US)
Pages (from-to)87480-87493
Number of pages14
JournalOncotarget
Volume8
Issue number50
DOIs
StatePublished - Jan 1 2017

Fingerprint

Ubiquitin-Activating Enzymes
Epithelial-Mesenchymal Transition
Ubiquitination
Breast
Epithelial Cells
Intercellular Signaling Peptides and Proteins
Carcinogenesis
Anoikis
Breast Neoplasms
rho GTP-Binding Proteins
Oncogene Proteins
Human Genome
Proteome
Ubiquitin
Cell Cycle Checkpoints
Small Interfering RNA
Extracellular Matrix
Homeostasis
Down-Regulation
Adenosine Triphosphate

Keywords

  • Breast cancer
  • Cell cycle
  • EMT
  • Rho GTPase
  • Ubiquitination

ASJC Scopus subject areas

  • Oncology

Cite this

@article{f3eca9e6a11445028d255bd0c0392b0b,
title = "The non-canonical ubiquitin activating enzyme UBA6 suppresses epithelial-mesenchymal transition of mammary epithelial cells",
abstract = "Ubiquitination plays critical roles in the regulation of oncoproteins and tumor suppressors during carcinogenesis. The two ubiquitin activating enzymes (E1) in human genome, UBA1 and UBA6, initiate ubiquitination by ATP-dependent activation of ubiquitin. Recent evidence suggests that UBA1 and UBA6 play partially overlapped yet distinct roles in controlling the proteome. Here we demonstrate that ubiquitination pathways initiated specifically by UBA6 set a suppressive barrier against critical steps of mammary carcinogenesis such as loss of polarity, anoikis resistance and epithelialmesenchymal transition (EMT). Mammary epithelial MCF-10A cells expressing shRNA against UBA6 fail in establishing cell cycle arrest in response to detachment from extracellular matrix, confluency with fully engaged cell-cell contact or growth factor deprivation. Moreover, UBA6-deficient MCF-10A cells undergo spontaneous EMT under growth factor deprivation and exhibit accelerated kinetics of TGF-β-induced EMT. The Rho-GTPase CDC42 is one of the specific targets of UBA6-initiated ubiquitination and plays a key role in the function of UBA6 in controlling epithelial homeostasis, since a CDC42 inhibitor, ML141, rescues UBA6-deficient cells from the EMT phenotype. Immunohistochemical analysis of human breast cancer tissues demonstrates that 38{\%} of invasive carcinomas express low or undetectable expression of UBA6, suggesting that downregulation of this non-canonical E1 plays a role in breast cancer development.",
keywords = "Breast cancer, Cell cycle, EMT, Rho GTPase, Ubiquitination",
author = "Xianpeng Liu and Limin Sun and Gursel, {Demirkan B.} and Chonghui Cheng and Sui Huang and Rademaker, {Alfred W.} and Khan, {Seema A.} and Jun Yin and Hiroaki Kiyokawa",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.20900",
language = "English (US)",
volume = "8",
pages = "87480--87493",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "50",

}

The non-canonical ubiquitin activating enzyme UBA6 suppresses epithelial-mesenchymal transition of mammary epithelial cells. / Liu, Xianpeng; Sun, Limin; Gursel, Demirkan B.; Cheng, Chonghui; Huang, Sui; Rademaker, Alfred W.; Khan, Seema A.; Yin, Jun; Kiyokawa, Hiroaki.

In: Oncotarget, Vol. 8, No. 50, 01.01.2017, p. 87480-87493.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The non-canonical ubiquitin activating enzyme UBA6 suppresses epithelial-mesenchymal transition of mammary epithelial cells

AU - Liu, Xianpeng

AU - Sun, Limin

AU - Gursel, Demirkan B.

AU - Cheng, Chonghui

AU - Huang, Sui

AU - Rademaker, Alfred W.

AU - Khan, Seema A.

AU - Yin, Jun

AU - Kiyokawa, Hiroaki

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Ubiquitination plays critical roles in the regulation of oncoproteins and tumor suppressors during carcinogenesis. The two ubiquitin activating enzymes (E1) in human genome, UBA1 and UBA6, initiate ubiquitination by ATP-dependent activation of ubiquitin. Recent evidence suggests that UBA1 and UBA6 play partially overlapped yet distinct roles in controlling the proteome. Here we demonstrate that ubiquitination pathways initiated specifically by UBA6 set a suppressive barrier against critical steps of mammary carcinogenesis such as loss of polarity, anoikis resistance and epithelialmesenchymal transition (EMT). Mammary epithelial MCF-10A cells expressing shRNA against UBA6 fail in establishing cell cycle arrest in response to detachment from extracellular matrix, confluency with fully engaged cell-cell contact or growth factor deprivation. Moreover, UBA6-deficient MCF-10A cells undergo spontaneous EMT under growth factor deprivation and exhibit accelerated kinetics of TGF-β-induced EMT. The Rho-GTPase CDC42 is one of the specific targets of UBA6-initiated ubiquitination and plays a key role in the function of UBA6 in controlling epithelial homeostasis, since a CDC42 inhibitor, ML141, rescues UBA6-deficient cells from the EMT phenotype. Immunohistochemical analysis of human breast cancer tissues demonstrates that 38% of invasive carcinomas express low or undetectable expression of UBA6, suggesting that downregulation of this non-canonical E1 plays a role in breast cancer development.

AB - Ubiquitination plays critical roles in the regulation of oncoproteins and tumor suppressors during carcinogenesis. The two ubiquitin activating enzymes (E1) in human genome, UBA1 and UBA6, initiate ubiquitination by ATP-dependent activation of ubiquitin. Recent evidence suggests that UBA1 and UBA6 play partially overlapped yet distinct roles in controlling the proteome. Here we demonstrate that ubiquitination pathways initiated specifically by UBA6 set a suppressive barrier against critical steps of mammary carcinogenesis such as loss of polarity, anoikis resistance and epithelialmesenchymal transition (EMT). Mammary epithelial MCF-10A cells expressing shRNA against UBA6 fail in establishing cell cycle arrest in response to detachment from extracellular matrix, confluency with fully engaged cell-cell contact or growth factor deprivation. Moreover, UBA6-deficient MCF-10A cells undergo spontaneous EMT under growth factor deprivation and exhibit accelerated kinetics of TGF-β-induced EMT. The Rho-GTPase CDC42 is one of the specific targets of UBA6-initiated ubiquitination and plays a key role in the function of UBA6 in controlling epithelial homeostasis, since a CDC42 inhibitor, ML141, rescues UBA6-deficient cells from the EMT phenotype. Immunohistochemical analysis of human breast cancer tissues demonstrates that 38% of invasive carcinomas express low or undetectable expression of UBA6, suggesting that downregulation of this non-canonical E1 plays a role in breast cancer development.

KW - Breast cancer

KW - Cell cycle

KW - EMT

KW - Rho GTPase

KW - Ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=85031722145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031722145&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.20900

DO - 10.18632/oncotarget.20900

M3 - Article

VL - 8

SP - 87480

EP - 87493

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 50

ER -